Eric J. Small, MD, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.Read More
Eric J. Small, MD, FASCO
University of California, San Francisco
San Francisco, CA
Dr. Eric J. Small is co-director of the Urologic Cancer Service and director of Urologic Oncology Research. His patient care and research focus is prostate cancer, immunotherapy and the mechanisms of resistance to standard therapies. He is a member of several professional medical societies including the American Society of Clinical Oncology and the American Urological Association. He is a member of the Therapy Consortium of The Prostate Cancer Foundation, the largest private source of prostate cancer research funding, and on the board of directors of the American Prostate Cancer Foundation. He chairs the Prostate Cancer Correlative Sciences Working Group of the Cancer and Leukemia Group B Cooperative Oncology Group. Small earned a bachelor's degree at Stanford University and a medical degree at Case Western Reserve University School of Medicine, where he graduated with honors. While in medical school, he completed a fellowship in pathology. He completed postgraduate residency training in internal medicine at Beth Israel Hospital and a fellowship in hematology and oncology at the UCSF Cancer Research Institute. He is a professor of medicine and urology at UCSF.